Clinical Parameters for Predicting the Survival in Patients with Squamous and Non-squamous-cell NSCLC Receiving PD-1 Inhibitor Therapy

We explored the associations between progression-free survival (PFS) after the initiation of PD-1 inhibitor therapy and the clinical parameters in patients with NSCLC. We reviewed the clinical data of patients with NSCLC treated with PD-1 inhibitor. Data of a total of 36 patients, including 16 patie...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pathology oncology research 2020-01, Vol.26 (1), p.327-333
Hauptverfasser:	Inomata, Minehiko, Hirai, Takahiro, Seto, Zenta, Tokui, Kotaro, Taka, Chihiro, Okazawa, Seisuke, Kambara, Kenta, Ichikawa, Tomomi, Imanishi, Shingo, Yamada, Toru, Miwa, Toshiro, Hayashi, Ryuji, Tobe, Kazuyuki
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antibodies, Monoclonal, Humanized - therapeutic use Biomarkers, Tumor - analysis Biomedical and Life Sciences Biomedicine C-reactive protein Cancer Research Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Epidermal growth factor receptors Female Humans Immune Checkpoint Inhibitors - therapeutic use Immunology L-Lactate dehydrogenase Lactic acid Life Sciences & Biomedicine Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - mortality Lymphocytes Male Middle Aged Nivolumab - therapeutic use Non-small cell lung carcinoma Oncology Original Article Pathology PD-1 protein Prognosis Progression-Free Survival Risk factors Science & Technology Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!